Macrophage Colony Stimulating Factor 1 Receptor CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1 Pipeline Review, H1 2018
Summary
Macrophage Colony Stimulating Factor 1 Receptor CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1 Macrophage colonystimulating factor MCSF is a secreted cytokine which influences hematopoietic stem cells to differentiate into macrophages or other related cell types. It plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. It promotes the release of proinflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. It plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. It required for normal male and female fertility. It promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration.
Macrophage Colony Stimulating Factor 1 Receptor CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1 pipeline Target constitutes close to 39 molecules. Out of which approximately 36 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in PreRegistration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 10, 7, 11 and 3 respectively.
Similarly, the universities portfolio in IND/CTA Filed and Preclinical stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Central Nervous System, Gastrointestinal, Genetic Disorders, Immunology and Respiratory which include indications Solid Tumor, Metastatic Melanoma, Breast Cancer, Gastric Cancer, Bladder Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, NonSmall Cell Lung Cancer, Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Gastrointestinal Stromal Tumor GIST, Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Ovarian Cancer, Bile Duct Cancer Cholangiocarcinoma, Fallopian Tube Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Pancreatic Cancer, Peritoneal Cancer, Recurrent Glioblastoma Multiforme GBM, Soft Tissue Sarcoma, Acral Lentiginous Melanoma, Follicular Thyroid Cancer, Gallbladder Cancer, Glioblastoma Multiforme GBM, Hepatocellular Carcinoma, Malignant Mesothelioma, Medullary Thyroid Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Papillary Thyroid Cancer, Renal Cell Carcinoma, Thyroid Cancer, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Anaplastic Thyroid Cancer, Angiosarcoma, Asthma, Bone Metastasis, Brenner Tumor, Cancer Pain, CharcotMarieTooth Disease Type I, Chondrosarcoma, Chronic Lymphocytic Leukemia CLL, Chronic Obstructive Pulmonary Disease COPD, Colon Cancer, Crohn's Disease Regional Enteritis, Endometrial Cancer, Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Gliosarcoma, Hematological Tumor, Inflammation, Lentigo Maligna Melanoma, Liposarcoma, Liver Cancer, Lung Adenocarcinoma, Malignant Ascites, Merkel Cell Carcinoma, Metastatic Bile Duct Cancer, Metastatic Biliary Tract Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Disorders, Neuroblastoma, Neuroendocrine Tumors, Neuroinflammation, NonHodgkin Lymphoma, Osteolysis, Osteosarcoma, Paraganglioma Glomus Jugulare Tumor, Peripheral Nerve Sheath Tumor Neurofibrosarcoma, Peripheral TCell Lymphomas PTCL, Pheochromocytoma, PostPolycythemia Vera Myelofibrosis PPVMF, Primary Progressive Multiple Sclerosis PPMS, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsing Remitting Multiple Sclerosis RRMS, Rhabdomyosarcoma, Salivary Gland Cancer, Sarcomas, Secondary Progressive Multiple Sclerosis SPMS, SmallCell Lung Cancer, Squamous NonSmall Cell Lung Cancer, Systemic Mastocytosis, Thymic Carcinoma, Thymoma Thymic Epithelial Tumor, Transitional Cell Carcinoma Urothelial Cell Carcinoma, Uveal Melanoma and Von HippelLindau Syndrome.
The latest report Macrophage Colony Stimulating Factor 1 Receptor Pipeline Review, H1 2018, outlays comprehensive information on the Macrophage Colony Stimulating Factor 1 Receptor CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1 targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Macrophage Colony Stimulating Factor 1 Receptor CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1
The report reviews Macrophage Colony Stimulating Factor 1 Receptor CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1 targeted therapeutics and enlists all their major and minor projects
The report assesses Macrophage Colony Stimulating Factor 1 Receptor CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Macrophage Colony Stimulating Factor 1 Receptor CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Macrophage Colony Stimulating Factor 1 Receptor CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Macrophage Colony Stimulating Factor 1 Receptor CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope